Marko Korenjak

Marko Korenjak

Auto-generated profile, based on publicly available information

Marko Korenjak

European Liver Patients Association (ELPA), Brussels, Belgium

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
LKLoreta A Kondili
Loreta A Kondili
JLJeffrey Lazarus
Jeffrey Lazarus
PJPeter Jepsen
Peter Jepsen
FMFrank Murray
Frank Murray
JSJörn M. Schattenberg
Jörn M. Schattenberg
MBMaria Buti
Maria Buti

6 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MCMarta Carol
Marta Carol
MPMartina Pérez-Guasch
Martina Pérez-Guasch
ESElsa Solà
Elsa Solà
MCMarta Cervera
Marta Cervera
SMSara Martínez
Sara Martínez
FIfor the LiverHope Consortium Investigators
for the LiverHope Consortium Investigators
Background and aims: Stigmatization is a well-documented problem of some diseases. Perceived stigma is common in alcohol-related liver disease and hepatitis C, but little information exists on stigma in patients with non-alcoholic fatty liver disease (NAFLD). Aim of the study was to investigate frequency and characteristics of perceived stigma among patients with NAFLD. Methods: One-hundred and ninety-seven patients seen at the liver clinic were included: a study group of 144 patients with NAFLD, 50 with cirrhosis (34 compensated, 16 decompensated), and a control group of 53 patients with alcohol-related cirrhosis. Demographic, clinical, and laboratory data were collected. Quality-of-life was assessed by chronic liver disease questionnaire (CLDQ). Perceived stigma was assessed using a specific questionnaire for patients with liver diseases categorized in 4 domains: stereotypes, discrimination, shame, and social isolation. Results: Perceived stigma was common in patients with NAFLD (99 patients, 69%) and affected all 4 domains assessed. The frequency was slightly higher, yet not significant, in patients with NAFLD cirrhosis vs those without (72% vs 67%, respectively; p = 0.576). In patients without cirrhosis perceived stigma was unrelated to stage of disease, since frequency was similar in patients with no or mild fibrosis compared to those with moderate/severe fibrosis (66% vs 68%, respectively). There were no differences in perceived stigma between patients with compensated cirrhosis and these with decompensated cirrhosis. Among patients with cirrhosis, stigmatization was more common in alcohol-related vs NAFLD-cirrhosis, yet differences were only significant in two domains. In patients with NAFLD, perceived stigma correlated with poor quality-of-life, but not with demographic or clinical variables. Conclusions: Perceived stigmatization is common among patients with NAFLD independently of disease stage, is associated with impaired quality-of-life, and may be responsible for stereotypes, discrimination, shame, and social isolation, which may affect human and social rights of affected patients.

1 January 2021 in Journal of Hepatology
Verified
Journal Article
Open access
ESElsa Solà
Elsa Solà
EPElisa Pose
Elisa Pose
DCDaniela Campion
Daniela Campion
SPSalvatore Piano
Salvatore Piano
OROlivier Roux
Olivier Roux
MPM. Pérez-Guasch
M. Pérez-Guasch
Management of decompensated cirrhosis is currently geared towards the treatment of complications once they occur. To date there is no established disease-modifying therapy aimed at halting progression of the disease and preventing the development of complications in patients with decompensated cirrhosis. The design of clinical trials to investigate new therapies for patients with decompensated cirrhosis is complex. The population of patients with decompensated cirrhosis is heterogeneous (i.e., different etiologies, comorbidities and disease severity), leading to the inclusion of diverse populations in clinical trials. In addition, primary endpoints selected for trials that include patients with decompensated cirrhosis are not homogeneous and at times may not be appropriate. This leads to difficulties in comparing results obtained from different trials. Against this background, the LiverHope Consortium organized a meeting of experts, the goal of which was to develop recommendations for the design of clinical trials and to define appropriate endpoints, both for trials aimed at modifying the natural history and preventing progression of decompensated cirrhosis, as well as for trials aimed at managing the individual complications of cirrhosis.

31 March 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PGPere Ginès
Pere Ginès
MTMaja Thiele
Maja Thiele
IGIsabel Graupera
Isabel Graupera
MSMiquel Serra-Burriel
Miquel Serra-Burriel
RKRobert J. de Knegt
Robert J. de Knegt
AKAleksander Krag
Aleksander Krag

17 August 2022 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
KSKatherine C. Sharrock
Katherine C. Sharrock
TNTeymur Noori
Teymur Noori
MAMaria Axelsson
Maria Axelsson
MBMaria Buti
Maria Buti
ADAsuncion Diaz
Asuncion Diaz
EDErika Duffell
Erika Duffell
This paper presents data on selected indicators to show progress towards elimination goals and targets for hepatitis B and hepatitis C in the 31 countries of the European Union (EU) and European Economic Area (EEA). A monitoring system was developed by the European Centre for Disease Prevention and Control, which combined newly collected data from EU/EEA countries along with relevant data from existing sources. Data for 2017 were collected from the EU/EEA countries via an online survey. All countries provided responses. In 2017, most countries reporting data had not reached prevention targets for childhood hepatitis B vaccination and for harm reduction services targeting people who inject drugs (PWID). Four of 12 countries had met the target for proportion of people living with chronic HBV diagnosed and seven of 16 met this target for hepatitis C. Data on diagnosed cases treated were lacking for hepatitis B. Of 12 countries reporting treatment data for hepatitis B, only Iceland met the target. This first collection of data across the EU/EEA highlighted major issues with data completeness and quality and in the indicators that were used, which impairs a clear overview of progress towards the elimination of hepatitis. The available data, whilst incomplete, suggest that as of 2017, the majority of the EU/EEA countries were far from meeting most of the 2020 targets, in particular those relating to harm reduction and diagnosis. It is critical to improve the data collected in order to develop more effective services for hepatitis prevention, diagnosis, and treatment that are needed in order to meet the 2030 elimination targets.

24 September 2025 in Patient Education and Counseling
Verified
Journal Article
Closed access
MMMichela Monaci
Michela Monaci
MRMateus Eduardo Romão
Mateus Eduardo Romão
SBSarah Bigi
Sarah Bigi
BCBeatrice Credi
Beatrice Credi
MKMarko Korenjak
Marko Korenjak
SBSerena Barello
Serena Barello